Coronavirus: what is the science behind UK plan to delay second dose of vaccines?
Experts divided over move to broaden gap between the two jabs in order to inoculate more people

Governments and health experts worldwide are considering whether to follow the UK in inoculating as many people as possible against Covid by giving them each just one dose rather than two.
The debate has been raging since the end of December, when Boris Johnson’s government announced plans to postpone giving the second dose of both the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines by up to 12 weeks.
Denmark has now unveiled plans to delay the second dose of both the Pfizer and forthcoming Moderna jabs by up to six weeks, and Germany is considering a similar move.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
But some experts are warning that “delaying could cause further virus mutations and render the shot ineffective”, while others “question whether recipients will be left more vulnerable”, says Politico.
“The only thing that is clear is that a second vaccination is absolutely essential because it triggers the necessary immune response, like a kind of booster,” adds Deutsche Welle.
The World Health Organization has “said it understood why a country facing the sort of increases in cases, hospitalisations and deaths that were happening in the UK might decide to go beyond the evidence” on administration of second doses, The Guardian reports.
But there is “very little empiric data from the trials that underpin this type of recommendation”, said Dr Joachim Hombach of the UN health agency’s strategic advisory group of experts on immunisation.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
According to the newspaper, “there is some evidence from trials of the Oxford/AstraZeneca vaccine that a late second dose, up to 12 weeks, does not interfere with the efficacy of the vaccine”.
But rival vaccine maker Pfizer has said that no data from its own clinical trials was available “to demonstrate that protection after the first dose is sustained after 21 days”.
Despite the misgivings, some experts believe the gains of delaying vaccine doses may outweigh the risks.
Thomas Mertens, from Germany’s public health agency, the Robert Koch Institute, has come out in favour of the UK plan. “Since the interval between the two vaccinations can very likely vary within wide limits and protection is already very good after one shot, it is certainly worth considering giving preference to the first injection in the event of a vaccine shortage,” he said.
The UK’s Joint Committee on Vaccination and Immunisation, an independent body that advises United Kingdom health departments on immunisation, reports that short-term vaccine efficacy from the first dose of the Pfizer-BioNTech vaccine is calculated at around 90%, and at around 70% for the AstraZeneca vaccine.
Given those high levels of protection, “models suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalisations than vaccinating a smaller number of people with two doses”, the committee’s experts argue.
Chas Newkey-Burden has been part of The Week Digital team for more than a decade and a journalist for 25 years, starting out on the irreverent football weekly 90 Minutes, before moving to lifestyle magazines Loaded and Attitude. He was a columnist for The Big Issue and landed a world exclusive with David Beckham that became the weekly magazine’s bestselling issue. He now writes regularly for The Guardian, The Telegraph, The Independent, Metro, FourFourTwo and the i new site. He is also the author of a number of non-fiction books.
-
America's academic brain drain has begun
IN THE SPOTLIGHT As the Trump administration targets universities and teachers, educators are eying greener academic pastures elsewhere — and other nations are starting to take notice
By Rafi Schwartz, The Week US Published
-
Why is Musk targeting a Wisconsin Supreme Court race?
Today's Big Question His money could help conservatives, but it could also produce a Democratic backlash
By Joel Mathis, The Week US Published
-
How to pay off student loans
The explainer Don't just settle for the default repayment plan
By Becca Stanek, The Week US Published
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
By The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published